Menu
Not yet recruiting NCT07149337

Assessing How the Body Responds to Increased Phosphate Intake, and How This Response Depends on Age and Sex.

No phase Interventional Aging Kidney Disease Mineral Metabolism

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Oral phosphate load.
Who it may be relevant to
Registry conditions: Aging, Kidney Disease, Mineral Metabolism. Basic parameters: 25 years — 70 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Center list to be confirmed — check the primary protocol.
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Official title

Assessing Human Phosphate Tolerance and Its Dependency on Age and Sex

Overview

Kidney function declines with age and this could affect phosphate balance after an acute phosphate load (increased phosphate intake). In daily life, we regularly experience acute phosphate loads through our diet. The aim of this clinical study is to determine whether the body's response to increased phosphate intake changes with age and whether there are sex differences in this response.

Detailed description

Forty subjects (males and females aged 18-25 or 63-70) will ingest an oral phosphate load, after which their body's response will be assessed by collecting blood and urine samples over a period of ten hours.

Interventions

  • Other Oral phosphate load
    Participants ingest an oral phosphate load containing 558 mg of phosphorus once.

Primary outcome measures

  • Phosphate in plasma [Time frame: The primary outcome will be measured 5 hours after the first blood collection on the day of the study and 4 hours after ingesting the oral phosphate load.]

Eligibility criteria

Inclusion criteria

  • Healthy volunteers 18-25 and 63-70 years old
  • 18.5 ≥ BMI < 26 kg/m2
  • 0.84 ≥ phosphate in plasma ≤ 1.45 mM
  • 2.20 ≥ calcium in plasma ≤ 2.50 mM
  • 15 ≥ PTH in plasma ≤ 65 pg/ml
  • eGFR ≥ 60 ml/min/1-73 m2
  • 90 ≥ Systolic blood pressure ≤ 140 mmHg
  • 60 ≥ Diastolic blood pressure ≤ 85 mmHg
  • No hematuria and no acute urinary tract infection
  • Ability and willingness to participate in the study
  • Voluntary signed inform consent

Exclusion criteria

  • Diabetes mellitus
  • Pregnancy
  • History of kidney stones
  • History of parathyroidectomy
  • History of anorexia nervosa
  • History of bulimia
  • History of solid organ transplantation.
  • Nephrolithiasis
  • Sarcoidosis
  • Chronic pancreatitis
  • Chronic diarrhea
  • Chronic liver disease
  • Complete distal renal acidosis (dRTA)
  • Cystinuria
  • Hypo- or hyperaldosteronism
  • Hyper- or hypotension
  • Hypernatremia
  • Gastrointestinal disorders
  • Known hypersensitivity reactions to azoic dyes, acetylsalicylic acid, as well as antirheumatic drugs and painkillers (prostaglandin synthesis inhibitors).

Intake of vitamin D and calcium supplements, phosphate, bisphosphonates, cinacalcet, denusomab, teriparatide, systemic glucocorticoids or mineralcorticoids, antiepileptics, carboanydrase inhibitors or diuretics

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: Yes

Study design

Allocation
N/A
Model
Single group
Masking
Open label
Primary purpose
Basic science

Study locations

Center list to be confirmed — check the primary protocol.

Identifiers

NCT: NCT07149337 · 2024-02538

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗